News | January 06, 2022
Aurobindo Pharma rolls out Molnaflu in India
The brand is now available pan-India through their distribution partner
The brand is now available pan-India through their distribution partner
10 implementation focused initiatives recommended to accelerate policy reforms, standardization of home care delivery services, and improve accessibility and affordability of care in tier II and tier III geographies
It is the generic version of molnupiravir
Healthy growth in domestic and emerging markets is expected to support revenue growth in the next few quarters
Molflu is expected to be available from early next week in pharmacies throughout the country with a particular focus on states with a high caseload of Covid-19.
Celltrion plans to provide dual treatment options for COVID-19; Regkirona for hospitalised patients and a nebulised cocktail therapy (CT-P63 in combination with Regkirona) for at- home settings
The Subject Expert Committee has recommended grant of permission to conduct Phase 3 trials under certain conditions
In India, healthcare has become one of the fastest-growing economic sectors which comprise hospitals, pharma companies, medical equipment and devices, medical tourism, health insurance, clinical trials etc
All the recommendations have been sent to the Drugs Controller General of India (DCGI) for final approval.
The Subject Expert Committee (SEC), on Covid-19 of the Central Drugs Standard Control Organisation (CDSCO) on Monday recommended granting permission to manufacture and market anti-Covid pill molnupiravir for restricted emergency use
Subscribe To Our Newsletter & Stay Updated
